CymaBay Therapeutics Inc. (NASDAQ:CBAY) shares saw an uptick in trading volume on Tuesday . 160,419 shares changed hands during mid-day trading, a decline of 8% from the previous session’s volume of 174,444 shares.The stock last traded at $2.50 and had previously closed at $2.44.

Several analysts have recently weighed in on CBAY shares. Roth Capital started coverage on shares of CymaBay Therapeutics in a research report on Friday, July 1st. They set a “buy” rating on the stock. Zacks Investment Research upgraded shares of CymaBay Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, June 20th. Finally, HC Wainwright lowered shares of CymaBay Therapeutics from a “buy” rating to a “neutral” rating and decreased their target price for the company from $6.00 to $2.25 in a research report on Wednesday, June 1st.

The firm’s 50 day moving average is $1.96 and its 200 day moving average is $1.84. The firm’s market cap is $58.38 million.

CymaBay Therapeutics (NASDAQ:CBAY) last announced its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.30) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.32) by $0.02. Equities research analysts anticipate that CymaBay Therapeutics Inc. will post ($1.20) earnings per share for the current year.

CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.